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Objective: Bisphosphonates are commonly used anti-osteoporotic drugs which have controversial effects
on joint diseases including osteoarthritis. Certain bisphosphonates have been shown to have anabolic
effects on cartilage which could have important ramiﬁcations for their proposed effects in vivo; however,
the underlying mechanisms are poorly understood. Thus, the purpose of this study was to characterize
the effects of clodronate on primary articular chondrocyte metabolism and to determine the underlying
signaling pathways responsible.
Design: The effects of clodronate and pamidronate on extracellular matrix (ECM) biosynthesis, accu-
mulation and MMP-13 activity were observed in high density, 3D cultures of bovine articular chon-
drocytes for up to 4 weeks were evaluated. Mechanisms were delineated by measuring intracellular Ca2þ
signaling and the effects of pharmacologic inhibition of the purinergic receptor pathway.
Results: Clodronate (100 mM) induced an anabolic effect (increased biosynthesis by 13e14%) which
resulted in an 89e90% increase in ECM accumulation after 4 weeks of culture and without an associated
effect on matrix turn-over. Stimulation by clodronate resulted in a 3.3-fold increase in Ca2þ signaling and
pharmacological inhibitor experiments suggested that the anabolic effects exerted by clodronate are
transduced through the purinergic receptor pathway.
Conclusions: These ﬁndings support the previous notion that certain bisphosphonates may be useful as
adjunctive therapies to potentially ameliorate progression of cartilage degeneration and improve
arthritis management.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Bisphosphonates are commonly used anti-osteoporotic drugs
that are chemically stable analogs of inorganic pyrophosphate (PPi).
They exert both physiochemical (mineralization inhibition) and
biological (osteoclast apoptosis) effects that make themwell suited.D. Waldman, Department of
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; Fax: 1-416-979-5083.
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ternational. Published by Elsevier Lto inhibit bone resorption1,2. As these molecules have also been
proposed to possess anti-inﬂammatory, chondro-protective, and
anti-catabolic effects, they may be promising drugs for the treat-
ment of osteoarthritis and rheumatoid arthritis3,4. Interestingly,
certain bisphosphonates (i.e., etidronate, clodronate) have been
shown to have anabolic effects on cartilaginous extracellular matrix
(ECM) biosynthesis5e7, which could have important ramiﬁcations
for their proposed effects on arthritis in vivo. However, recent
clinical studies have been relatively inconclusive8e13.
Although the physiochemical effects of bisphosphonates on
mineralization are well understood, the molecular mechanisms of
bisphosphonates on cellular function are more variable, and have
been broadly categorized into two groups based on drug structure.
After cellular uptake by ﬂuid-phase endocytosis (pinocytosis)14,15,td. All rights reserved.
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zoledronate) interfere with the mevalonate biosynthetic pathway
that leads to inhibition of bone resorption by disrupting both
osteoclast function and survival16,17. Alternatively, the non-
nitrogen-containing bisphosphonates (e.g., etidronate, clodronate)
are metabolized into the non-hydrolyzable ATP analog adenosine
50(b,g-dichloromethylene) triphosphate (AppCCl2p) by aminoacyl-
tRNA synthetases18e20. In osteoclasts, this metabolite is believed to
be responsible for inducing apoptosis by inhibiting mitochondrial
metabolism (through the disruption of ATP translocation)21 d
which is believed to be the primary means by which these
bisphosphonates inhibit bone resorption22. Less is known about the
effects of bisphosphonate on articular cartilage. Chondrocytes are
known to release ATP in response to mechanical or osmotic stimuli
which is then utilized as an autocrine/paracrine signal23,24. This
pathway (termed the purinergic receptor pathway) is not exclusive
to chondrocytes but also functions in other cells that utilize
extracellular ATP as a mechanotransduction signal25,26. Due to the
structural similarity between ATP and the non-hydrolyzable
bisphosphonate metabolite AppCCl2p, we propose that non-
nitrogen containing bisphosphonates elicit an anabolic response
in chondrocytes through extracellular transport of the metabolite
AppCC2p and its interactions with components of the purinergic
receptor pathway. Thus, the purpose of this study was to charac-
terize the anabolic effects of clodronate on chondrocytes and to
determine the underlying mechanism.
Materials and methods
Cell isolation and high-density 3D culture
High-density 3D chondrocyte cultures were generated from
isolated chondrocytes harvested from calf (12e18 months old)
metacarpal-phalangeal articular cartilage obtained from a local
abattoir after slaughter (Brian Quinn's Meats Ltd., Yarker, ON,
Canada) by sequential enzymatic digestion, as described previ-
ously27. Tissue was obtained from several joints (up to four per
isolation) and pooled together to collect a sufﬁcient cell population.
The cells were seeded on the surface of type II collagen-coated
Millicell™ ﬁlters (Millipore, Billerica, MA, USA) in high-density
3D culture (2  106 cells/ﬁlter or 35,000 cells/mm2)27 and main-
tained in Ham's F12 media containing 10 mM glucose supple-
mented with 20% fetal bovine serum (FBS), 100 mg/mL ascorbate
and 20 mM HEPES (N-2-hydroxyethylpiperazine-N0-ethanesulfonic
acid) (Sigma-Aldrich Ltd., Burlington, ON, Canada). The cultures
were maintained in an incubator at 37C with 95% relative hu-
midity supplemented with 5% CO2: 95% atmospheric air. The cul-
ture medium (1 mL per ﬁlter) was changed every 2e3 days.
Bisphosphonate supplementation and assessment of ECM synthesis
To determine the short-term effect of bisphosphonates on ECM
synthesis, cultures were supplemented with media containing
either clodronate or pamidronate (Sigma-Aldrich Ltd.) 2 days after
seeding at varying concentrations (0, 1, 10, and 100 mM) and incu-
bated in the presence of both [35S]SO4 (5 mCi/culture) to label
proteoglycans and [3H] proline (5 mCi/culture) to label collagen for a
period of 24 h. Although proline can be incorporated into different
proteins, in chondrocyte cultures approximately 90% of proline
becomes incorporated into collagen28,29. The unincorporated
isotope from the tissue cultures was removed by gently washing
the samples three times in phosphate-buffered saline29. Cultures
were then digested by papain (40 mg/ml in 20 mM ammonium
acetate, 1 mM EDTA, and 2 mM DTT) for 48 h at 65C. The accu-
mulation of newly synthesized proteoglycan and collagen in thematrix was then estimated by quantifying radioisotope incorpo-
ration from aliquots of the papain digest using a b-liquid scintilla-
tion counter (Beckman Coulter LS6500, Mississauga, ON, Canada).
The amounts of synthesized molecules were calculated relative to
the DNA content of the tissue, determined from aliquots of the
papain digest using the Hoechst dye 33258 assay30.Long-term culture and assessment of ECM accumulation
Bisphosphonate supplemented cultures were maintained for a
period of 4 weeks to determine the effect on ECM accumulation. In
these experiments, only the high concentrations of bisphospho-
nates (100 mM of pamidronate or clodronate) were used based on
the maximal effect observed during the previous short-term ECM
synthesis experiments. After long-term culture, accumulated tis-
sues were removed from the ﬁlter units and weighed (wet
weight). Tissues were then digested by papain (as described
earlier) and stored at 20C until analysis. Aliquots of the digest
were assayed separately for proteoglycan, collagen and DNA con-
tents. The proteoglycan content was estimated by quantifying the
amount of sulfated glycosaminoglycans using the dimethyl-
methylene blue dye binding assay31. Collagen content was esti-
mated from the determination of the hydroxyproline content.
Aliquots of the papain digest were hydrolyzed in 6 N HCl at 110C
for 18 h and the hydroxyproline content of the hydrolyzate was
then determined using chloramine-T/Ehrlich's reagent assay32.
Collagen content was estimated assuming hydroxyproline ac-
counts for 10% of the total collagen mass in cartilage33. The DNA
content was also determined from aliquots of the papain digest (as
described earlier)30.Histological and immunohistochemical evaluation
Representative cultures from the long-term experiments were
harvested and ﬁxed overnight in 4% paraformaldehyde (in 0.1 M
phosphate buffer, pH 7.2), dehydrated in graded ethanol solutions
and embedded in parafﬁn at 65C. Thin (5 mm thick) sections were
cut and mounted on Superfrost slides (Fisher Scientiﬁc, Mis-
sissauga, ON, Canada) and dried for 24 h at 37C. Sections were
stained with hematoxylin & eosin (H&E) or assessed for localiza-
tion of collagen types I and II by immunohistochemistry. Brieﬂy,
after deparafﬁnization and dehydration, sections were enzymati-
cally treated with 0.05% of trypsin (pH 7.8) for 30 min at 37C to
facilitate antibody binding. Endogenous peroxidase activity was
blocked with 1% H2O2 and 1% bovine serum albumin (BSA) in
phosphate buffer for 30 min. Sections were then incubated with
mouse monoclonal antibodies against collagen type I (I-8H5 at
40 mg/mL; Daiichi Fine Chemicals Co Ltd, Takaoka, Japan) or
collagen type II (II-II6B3 at 187 mg/mL; Developmental Studies
Hybridoma Bank, Iowa City, IA, USA) all diluted in phosphate
buffer (pH 7.4) containing 1% BSA overnight at 4C. Following
primary antibody incubation, sections were rinsed in PBS (pH 7.4),
and incubated with biotinylated anti-mouse secondary antibodies
(Vector Laboratories Inc., Burlingame, CA, USA) using the Vectas-
tain Elite ABC kit (Vector Laboratories) for 2 h at room tempera-
ture, followed by incubation with diaminobenzidine (DAB) for
6 min at room temperature. The sections were counter-stained
with Harris' hematoxylin and mounted in permanent mounting
medium. Non-speciﬁc staining was assessed by replacement of the
primary antibody with non-immune mouse serum. Stained sec-
tions were examined by light microscopy using a Zeiss Axio-Image
M1 microscope (G€ottingen, Germany). All the experiments were
completed at least three times with no positive staining detected
in the negative controls.
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Additional long-term cultures were used to determine the effect
of bisphosphonates on MMP-13 activity. MMP-13 mediates ECM
catabolism, reﬂects altered chondrocyte phenotype34 and is amajor
factor in the matrix degradation that occurs in osteoarthritis35. In
these experiments, the serum concentrationwas decreased to 5% at
the last feeding prior to harvest to reduce potential interference
with the MMP-13 activity assay. After harvest, protein was extrac-
ted from the tissue cultures following a protocol described by
Nielson et al.36 Samples were snap frozen in liquid N2, pulverized
and then homogenized (2  30 s) (Power Gen 125, Fisher Scientiﬁc,
Hampton, NH, USA) in the presence of extraction buffer (TriseHCl
0.05 M, NaCl 0.1 M, Triton X-100 0.1% (v/v), pH 7.4) and one com-
plete mini EDTA-free protease inhibitor cocktail tablet (Roche Di-
agnostics, Laval, QC, Canada) per 10 mL of buffer. Samples were
centrifuged for 10 min at 7500 g and 4C. The supernatant was
collected and further centrifuged at 10,000 g for 10 min at 4C and
then stored at 20C until analysis. To determine the amount of
active MMP-13, a FRET based assay using the Mca MMP-13 FRET
substrate (MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2) (AnaSpec Inc.,
Fremont, CA, USA) which ﬂuoresces when cleaved by MMP-1337.
Equal volumes of the Mca MMP-13 FRET substrate and protein
extracts were combined in 20% DMSO (v/v) and mixed with assay
buffer (200 mM NaCl, 50 mM Tris base CaCl2, 20 mM ZnSO4, and
0.05% BRIJ 35 (w/v), pH 7.5) then incubated at 37C with 95% hu-
midity for 18 h in the dark. After incubation, ﬂuorescence was
measured at 325 nm excitation and 393 nm emission with Mca
MMP FRET ﬂuorescence peptides (MCA-Pro-Leu-OH) reconstituted
in 20% DMSO (v/v) used as assay standards. MMP-13 activity was
calculated relative to the DNA content of the tissue culture (as
described earlier)30.Assessment of intracellular calcium signaling and the mechanisms of
drug import/export and involvement of the purinergic receptor
pathway
As many of the cellular responses to extracellular ATP are
mediated through intracellular calcium signaling38e40, the mech-
anism by which clodronate affected chondrocyte biosynthesis was
investigated by assessing intracellular calcium transients. Isolated
chondrocytes were resuspended at a concentration of
20  106 cells/mL in Ham's F-12 with 25 mM HEPES. A 4% w/v
solution of type VII lowmelt agarose (Sigma-Aldrich) was prepared
in PBS (pH 7.4) and mixed in equal parts with the cell suspension to
form 2% agarose gels with a concentration of 10  106 cells/mL. The
suspensionwas poured into petri dishes and allowed to gel at room
temperature. Individual cell-seeded hydrogel constructs (4 mm
dia.  4 mm height) were then created using a 4 mm biopsy punch
and cultured in complete media for 2 days. Cell-seeded constructs
were then incubated in the intracellular calcium ion dye Fluo-4 AM
(3 mM; Life Technologies, Carlsbad, CA, USA) in complete media for
90 min in the dark, followed by washing for 10 min in completeTable I
Pharmacological inhibitors (all previously used on chondrocytes) used to block elements
Inhibitor Carrier Target
Suramin Media Broad spectrum P2 rec
Reactive blue 2 (RB2) Media P2Y receptor inhibitor4
Brilliant blue G (BBG) Media P2X receptor inhibitor4
Apyrase Media Deplete extracellular A
FFA DMSO Connexin 43 hemi-cha
U73122 Chloroform PLC inhibitor40
Dansylcadaverine Methanol Pinocytosis inhibitor15media. In the ﬁrst set of experiments, the time course of Ca2þ
signaling as a result of bisphosphonate stimulationwas assessed by
transferring the labeled constructs to media containing either
clodronate or pamidronate (100 mM) and measuring resultant Ca2þ
transients at 30 min intervals for a period of up to 180 min. At each
time point, the mid-section of the construct was imaged by
confocal microscopy (IX81, Olympus Canada, Richmond Hill, ON,
Canada) with a 10 objective (ex: 488 nm; em: 516 nm). Images
(640  640 pixels) were captured every 5 s over a 5 min imaging
period. Captured images were then analyzed using ImageJ software
(US National Institutes of Health, Bethesda, MD, USA) by selecting
circular regions of interest around individual cells experiencing
Ca2þ transients and measuring the change in intensity over the
series of collected images. Fluorescent intensity traces (as a func-
tion of time) were plotted and the number cells experiencing
multiple transients (more than one) were counted. Once the
pattern of calcium transients elicited by clodronate was estab-
lished, we set out to delineate the mechanisms involved. In these
studies, we used pharmacologic inhibitors of the purinergic re-
ceptor pathway as well as inhibitors of drug import or efﬂux
mechanisms. Cell-seeded gel constructs were pre-incubated in the
presence of pharmacological inhibitors to block discrete elements
of the ATP-purinergic receptor pathway (Table I) prior to clodronate
stimulation (100 mM). It was also determined whether the blockade
of clodronate import (dansylcadaverine) and AppCCl2p efﬂux
(ﬂufenamic acid (FFA)) could be rescued by direct stimulation of the
purinergic receptors by ATP (100 mM). In the inhibitor and rescue
experiments, confocal imaging to assess resultant changes in Ca2þ
transients was assessed at the optimal time identiﬁed in the pre-
vious study.Statistical analyses
Chondrocytes isolated from a single animal (from up to four legs
of the same animal) were used for each experiment. Each experi-
ment was repeated three times with chondrocytes from three
different animals (N ¼ 3 animal donors). Within each experiment,
replicates of 2e3 samples per group were generated and all
quantitative data was normalized to the control of the same animal
donor. Statistical analyses were then performed on the composite
data obtained from all three experiments (total sample size of
n ¼ 6e9 samples/group). Note that due to the relatively small
number of samples created from each animal, the effect of animal
donor was not incorporated into the statistical models. All results
were expressed as the mean (lower 95% conﬁdence interval limit,
upper 95% conﬁdence interval limit). Collected data was analyzed
statistically (SPSS version 16, SPSS Inc., Chicago, IL, USA) using a
one-way or two-way ANOVA and the Tukey's post-hoc test (where
appropriate) depending on the experimental design. One-way
ANOVA testing was used to determine the effect of bisphospho-
nate dose and the time course of Ca2þ signaling; whereas two-way
ANOVA testing was used to determine the effect of each speciﬁc
inhibitor used to block various elements of the ATP-purinergicof the ATP-purinergic receptor pathway
Concentration Pre-incubation time
eptor inhibitor41 100 mM 30 min
2 100 mM 30 min
3 50 mM 30 min
TP (ATPase)41 10 units/mL 30 min
nnel blocker41 25 mM 30 min
10 mM 30 min
500 mM 240 min
Fig. 1. The effect of short-term clodronate and pamidronate exposure on collagen and
proteoglycan synthesis by articular chondrocytes. The effect of clodronate and
pamidronate on collagen (A) and proteoglycan (B) synthesis by chondrocytes was
determined 24 h after exposure to the bisphosphonate. Data was normalized to control
(as described in the Methods) and expressed as the meanwith errors bars representing
the 95% conﬁdence interval (N ¼ 3 donors; total n ¼ 6 samples/group) and open circles
representing individual data points. *denotes a signiﬁcance difference between all
other groups (panel A: P ¼ 0.018; panel B: P ¼ 0.036).
Table II
Effect of the bisphosphonates on cartilaginous tissue formation andMMP-13 activity. Data
(lower 95% conﬁdence interval limit, upper 95% conﬁdence interval limit) (N ¼ 3 donors
Control
Wet weight [mg/culture] 1.0 (0.8, 1.2)
Proteoglycans [mg/culture] 1.0 (0.8, 1.2)
Collagen [mg/culture] 1.0 (0.8, 1.2)
DNA [mg/culture] 1.0 (0.8, 1.2)
Proteoglycans/Wet weight [mg/mg] 1.0 (0.9, 1.1)
Proteoglycans/DNA [mg/mg] 1.00 (0.92, 1.08
Collagen/Wet weight [mg/mg] 1.0 (0.7, 1.3)
Collagen/DNA [mg/mg] 1.0 (0.7, 1.3)
MMP-13 activity [ng substrate hydrolyzed/mg DNA] 1.0 (0.6, 1.4)
a Signiﬁcantly different from all other groups (P ¼ 0.001).
b Signiﬁcantly different from all other groups (P ¼ 0.007).
c Signiﬁcantly different from all other groups (P < 0.001).
d Signiﬁcantly different from all other groups (P ¼ 0.022).
e Signiﬁcantly different from all other groups (P ¼ 0.048).
f Signiﬁcantly different from all other groups (P ¼ 0.010).
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tistical tests for both normality and equal-variance. Signiﬁcance
was deﬁned by P-values less than 0.05 and trends associated with
P-values between 0.05 and 0.1.
Results
Effect of bisphosphonates on cartilaginous ECM synthesis, ECM
accumulation, and MMP-13 activity
To determine the short-term effect of bisphosphonate stimula-
tion on the synthesis of cartilaginous ECM macromolecules, iso-
lated articular chondrocytes were seeded in high-density 3D
culture supplemented with varying doses of clodronate or
pamidronate (0e100 mM) 2 days after seeding. As determined by
radiolabel incorporation, only stimulation by 100 mM clodronate
signiﬁcantly upregulated ECM synthesis by 13e14% (collagen:
P ¼ 0.018, proteoglycans: P ¼ 0.036; Fig. 1). In contrast, pamidro-
nate had no effect on ECM synthesis under any of the doses
investigated (Fig. 1). Bisphosphonate stimulation (clodronate or
pamidronate) also had no effect on tissue cellularity (data not
shown).
To determine the long-term effect of bisphosphonate stimula-
tion on the growth of cartilaginous tissue formed in vitro, high-
density 3D cultures were cultured in the presence of clodronate
or pamidronate (at 100 mM) for a period of 4 weeks. Clodronate
induced a sustained anabolic effect as observed by an increase in
tissue wet weight by 66% (P ¼ 0.001). Further analysis of the
accumulated ECM revealed that stimulation by clodronate resulted
in a signiﬁcant increase of 89e90%, in collagen (P < 0.001) and
proteoglycans (P¼ 0.007) compared to control (Table II). In contrast
to the short-term studies, long-term culture in the presence of
clodronate appeared to elicit a modest proliferative response with
the stimulated cultures having an approximate 25% higher DNA
content (P ¼ 0.022) compared to control (Table II). Similar to the
results of short-term stimulation, long-term culture with pamidr-
onate induced no apparent effect on ECM accumulation (wet
weight: P ¼ 0.655, collagen: P ¼ 0.196, proteoglycans: P ¼ 0.876,
DNA: P ¼ 0.718). Histological assessment of the developed tissues
displayed the same trends in terms of tissue thickness as a result of
long-term bisphosphonate stimulation with only clodronate
inducing an anabolic effect (Fig. 2). Immunohistochemical evalua-
tion conﬁrmed that the increased collagen accumulation as a result
of long-term culture with clodronate was primarily type II with no
detectable presence of type I collagen synthesized by the cells
(Fig. 2). Maintenance of a healthy chondrocyte phenotype andwas normalized to control (as described in the Methods) and expressed as the mean
; total n ¼ 8 samples/group)
100 mM pamidronate 100 mM clodronate
1.1 (0.8, 1.4) 1.66 (1.60, 1.72)a
1.1 (0.8, 1.4) 1.9 (1.5, 2.3)b
0.8 (0.6, 1.0) 1.89 (1.83, 1.95)c
0.9 (0.8, 1.0) 1.2 (1.0, 1.4)d
1.0 (0.9, 1.1) 1.1 (0.9, 1.3)
) 1.2 (0.9, 1.5) 1.5 (1.2, 1.8)e
0.9 (0.6, 1.2) 1.2 (1.1, 1.3)
0.8 (0.6, 1.0) 1.6 (1.3, 1.9)f
1.0 (0.8, 1.2) 1.3 (0.8, 1.8)
Fig. 2. The effect of long-term exposure to clodronate and pamidronate on chondrocyte ECM. Histological and immunohistochemical assessment of cartilaginous tissue constructs
after 4 weeks of exposure to clodronate (100 mM) or pamidronate (100 mM). Tissue sections were stained with hematoxylin and eosin (H&E) as well as collagen II and collagen I
assessed by immunohistochemical methods (positive protein staining appears in brown). Original magniﬁcation of 40 and the scale bar represents 100 mm.
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13 activity after bisphosphonate treatment (P ¼ 0.560; Table II).Effect of bisphosphonates on intracellular calcium signaling and the
delineation of membrane transport and signaling mechanisms
Additional experiments were conducted to determine whether,
like ATP, clodronate signals by inducing intracellular Ca2þ tran-
sients. Fluo-4 AM loaded chondrocytes in suspended in agarose
hydrogels were stimulated with clodronate (100 mM) and imaged
by confocal microscopy. Measurement of ﬂuorescent intensity over
the 5 min imaging window showed that the cells (control and
bisphosphonate stimulated) experienced Ca2þ transients of similar
magnitude and duration (Fig. 3). However, after 30 min of incu-
bation, the number of Ca2þ transients experienced signiﬁcantly
increased upon stimulation with clodronate as opposed to
pamidronate (fold changes in Ca2þ signaling; control: 1.0 (0.9, 1,1),
clodronate: 3.3 (3.1, 3.5), pamidronate: 1.1 (0.8,1.4); P < 0.001, n¼ 8).
This delay in signaling supports the concept that a drug metabolite
is responsible for the observed calcium transients. The inducedFig. 3. The effect of clodronate on calcium transients in chondrocytes. Overall cell
ﬂuorescent intensity (arbitrary units) of individual chondrocytes pre-incubated with
Fluo-4 using confocal microscopy is shown here for cultures supplemented with (top
trace) or without (bottom trace) clodronate (100 mM). Fluorescent intensity was
determined from images captured every 5 s over a 300 s imaging period.Ca2þ signaling response as a result of clodronate stimulation was
relatively unchanged 120 min after stimulation which then started
to decline upon longer durations (data not shown). For this reason,
all subsequent experiments were conducted with Ca2þ signaling
measured 30 min after stimulation. In the second series of exper-
iments, cultures were pre-incubated in the presence of different
inhibitors to block discrete elements of the purinergic receptor
pathway prior to stimulation by clodronate. Broad spectrum puri-
nergic P2 receptor inhibitors (suramin, reactive blue 2, brilliant blue
G) each appeared to inhibit clodronate induced Ca2þ signaling by
varying degrees [Fig. 4(a)]. Both suramin (a general P2 receptor
antagonist) and reactive blue 2 (P2Y receptor antagonist) induced
complete inhibition (P < 0.001) whereas brilliant blue G (P2X re-
ceptor antagonist) only partially inhibited the response (by ~70%;
P ¼ 0.030). Downstream signaling through the purinergic receptor
pathway was conﬁrmed as the phospholipase C (PLC) inhibitor
U73122 also completely inhibited clodronate induced Ca2þ
signaling [P ¼ 0.006, Fig. 4(a)]. Similarly, while the hemi-channel
blocker FFA also completely inhibit clodronate induced Ca2þ
signaling [P < 0.001, Fig. 4(a)]; however, the release of extracellular
ATP appeared not to be involved as depletion by apyrase had no
measurable effect on Ca2þ signaling [Fig. 4(a)]. There was also a
trend towards complete inhibition of the response with dansylca-
daverine, a pinocytosis (ﬂuid-phase endocytosis) inhibitor
[P ¼ 0.093, Fig. 4(a)]. In the last series of experiments, it was
determined whether the inhibitory effects of FFA and dansylcada-
verine could be rescued by direct stimulation of the purinergic
receptors. Direct stimulation of the purinergic receptor pathway by
ATP (100 mM) rescued the inhibited Ca2þ signaling response to
similar levels observed in the previous experiments [P < 0.001,
Fig. 4(b)].Discussion
This study demonstrates that clodronate induces an anabolic
effect in chondrocyte cultures and that the response appears to be
mediated by export of an intracellular ATP-analog which then
signals through the purinergic receptor pathway. Upon stimulation
by clodronate, short-term matrix synthesis was upregulated by a
relatively small degree (13e14%); however, there was a sustained
effect with 89e90% increase in proteoglycan and collagen content
in clodronate-treated cultures observed over the long-term. Inter-
estingly, this response occurred without alterations in chondrocyte
phenotype, or increased catabolism as determined by MMP-13
Fig. 4. The effect of purinergic receptor pathway inhibitors on calcium transients induced by clodronate. (A) Fold changes in intracellular Ca2þ signaling of Fluo-4 labeled chon-
drocytes stimulated by clodronate (100 mM) after pre-incubation with pharmacological inhibitors to block discrete elements of the purinergic receptor pathway (Table I). Confocal
images (640  640 pixels) were captured every 5 s over a 300 s imaging period and the number of cells experiencing multiple transients were counted. For each inhibitor, the
number of cells experiencing multiple transients was normalized to vehicle-only control (shown in parentheses) and expressed as the mean with errors representing the 95%
conﬁdence interval (N ¼ 3 donors; total n ¼ 8e9 samples/group) and open circles representing individual data points. (B) Fold changes in intracellular Ca2þ signaling of Fluo-4
labeled chondrocytes pre-incubated with FFA or dansylcadaverine (Table I) and stimulated by clodronate (100 mM) with or without additional ATP stimulation (100 mM). The
number of cells experiencing multiple transients was normalized to vehicle-only control and expressed as the mean with errors representing the 95% conﬁdence interval (N ¼ 3
donors; total n ¼ 6e8 samples/group) and open circles representing individual data points. A,Bdenotes a signiﬁcant effect of clodronate (P < 0.001 and P ¼ 0.045, respectively),
a,b,cdenotes a signiﬁcant effect of the inhibitor (P < 0.001, P ¼ 0.030 and P ¼ 0.006, respectively), and ddenotes a trend of the inhibitor (P ¼ 0.093). *denotes a signiﬁcant effect of ATP
(P < 0.001).
R.G. Rosa et al. / Osteoarthritis and Cartilage 22 (2014) 1327e13361332activity. These results were similar to several other studies that
reported an anabolic effect of clodronate in chondrocytes5,6.
Alternatively, pamidronate had no apparent effect on ECM syn-
thesis, accumulation or matrix turn-over. The difference in these
responses was most likely attributed to the differences in
bisphosphate structure. Pamidronate is a nitrogen-containingbisphosphonate that has been proposed to disrupt osteoclast
function through interference with the mevalonate biosynthetic
pathway16,17. Clodronate, a non-nitrogen containing bisphospho-
nate, has been shown to become metabolized into the non-
hydrolyzable ATP analog adenosine 50(b,g-dichloromethylene)
triphosphate (AppCCl2p) by aminoacyl-tRNA synthetases18e20.
Fig. 5. Schema of proposed clodronate signaling pathway. Proposed clodronate signaling pathway. Pharmacological inhibitors used to block discrete elements of the signaling
pathway (irrespective of their effect) are shown.
R.G. Rosa et al. / Osteoarthritis and Cartilage 22 (2014) 1327e1336 1333Due to the structural similarities between ATP and AppCCl2p,
we hypothesized that this metabolite could then act via the ATP-
purinergic receptor pathway leading to an anabolic response.
Chondrocytes utilize the purinergic receptor pathway as part of the
mechanotransduction cascade in which ATP is released through
connexin 4344, pannexin 1 hemi-channels45 and/or ANK46 into the
extracellular spacewhere it can bind and signal through a variety of
purinergic P2 receptors. Both P2X and P2Y receptors have been
identiﬁed on articular chondrocytes23,24. P2Y receptors are G-pro-
tein coupled receptors which utilize the IP3 e Ca2þ second
messenger system, leading to the stimulation of ECM gene
expression and protein synthesis24, while P2X receptors may have
both catabolic functions and regulate hemichannel activity,
through their interactions with pannexins45 In the present study,
further examination of the underlying signaling pathways revealed
that stimulation by clodronate, and not pamidronate, resulted in a
3-fold increase in Ca2þ signaling, which could be inhibited through
pharmacological inhibition of discrete elements of the purinergic
receptor pathway (Fig. 5). Involvement of the purinergic receptor
pathway was also conﬁrmed by additional experiments showing
that this response could be rescued by direct stimulation of the
purinergic receptors (P2Y) by ATP; which have been shown to elicit
an anabolic response in both bovine and human chondrocytes47e50.
After uptake by ﬂuid-phase endocytosis (pinocytosis), clodronate is
metabolized into AppCCl2p which is then released into the extra-
cellular space likely through hemi-channels. As approximately 70%
of clodronate induced Ca2þ signaling was abolished by inhibiting
P2X receptors, this suggests that the released AppCCl2p may bind
to the P2X7 or P2X4 receptor leading to additional release through
its known association with pannexin 1, a channel forming glyco-
protein that primarily responsible for ATP release45. Extracellular
AppCCl2p then binds to P2Y receptors (most likely P2Y2) leading to
the release of intracellular calcium from intracellular storesthrough the IP3 second messenger system. This proposed pathway
is also supported by the previous observation that clodronate can
induce Ca2þ signaling in carcinoma cells51.
There were a few limitations of the present study. The most
notable was that we were unable to measure the generation of the
clodronate metabolite AppCCl2p. Similarly, as it is presently not
known which speciﬁc aminoacryl transfer RNAases are involved in
the generation of AppCCl2p, it was not possible to perform any
speciﬁc inhibitor studies to block the generation of the metabolite.
Aminoacryl transfer RNAases are a large family of enzymes with
numerous isoforms and there are no broad spectrum inhibitors
currently available. In spite of these limitations, the underlying
mechanism(s) responsible for the anabolic effect of clodronate on
chondrocytes appears to involve the generation of a non-
hydrolyzable ATP analog. Studies conducted in the presence of
apyrase (to degrade extracellular ATP) had no apparent effect and
the response was inhibited by blocking either P2X or P2Y receptors
e both of which have high afﬁnity for ATP and ATP analogs. Simi-
larly, the pharmacologic inhibitors used in this study have potential
off-target effects which do not allow for the direct inhibition of this
pathway during long-term culture. However, previous studies have
demonstrated that purinergic receptors agonists (e.g., ATP) elicit an
anabolic response in both bovine and human chondrocytes under
similar concentrations to the bisphosphonate concentrations used
in the present study47e50. There is also uncertainty related to the
levels of clodronate in cartilage achieved in vivo. However, previous
studies involving intra-articular injections of clodronate showed
positive effects of clodronate with doses in the range of 104 to
103 M11 which were comparable to levels inwhich anabolic effects
on chondrocytes were observed. Lastly, as these studies were
conducted using healthy bovine chondrocytes, future studies will
need to be conducted with mature human chondrocytes as the
choice of the chondrocyte species, age, and (lack of) disease state
R.G. Rosa et al. / Osteoarthritis and Cartilage 22 (2014) 1327e13361334may have each contributed to the observed response. However,
several studies using bovine chondrocytes have elucidated the
mechanism of release41,44 as well as the subsequent anabolic ef-
fect47,48 of purinergic receptor agonists indicating their utility for
understanding the role of the purinergic receptor pathway in
chondrocyte metabolism.
As bisphosphonates have been ascribed to possess anti-
inﬂammatory, chondro-protective, and anti-catabolic effects they
have been suggested to be promising drugs for the treatment of
arthritis. While recent reports have concluded that bisphospho-
nates do not have any signiﬁcant clinical effects on either disease
activity or pain in osteoarthritis8 and rheumatoid arthritis9, there
has been little attempt to distinguish clinical efﬁcacy based on
bisphosphonate type. Interestingly, while the nitrogen-containing
bisphosphonates risedronate, alendronate and zoledronate are
generally ineffective8,9, the non-nitrogen containing bisphospho-
nate clodronate appears to be have some limited effects in reducing
pain associated with both osteoarthritis10,11 and rheumatoid
arthritis12,13. Only a single study involving clodronate showed no
effect of the treatment, which the authors attributed to the method
of delivery (iv. infusion as opposed to liposomal encapsulation)52.
The observed anabolic effect of clodronate may serve to limit or
restrict cartilage degradation as a result of osteoarthritis and
rheumatoid arthritis. However, the signiﬁcance of this effect and
whether it can be extended to all non-nitrogen containing
bisphosphonates, including etidronate, and tiludronate is currently
unclear53,54. This proposed mechanism of action may be also one of
several through which bisphosphonates might ameliorate cartilage
damage. For example, bisphosphonates also bind and inactivate
basic calcium phosphate crystals, which are common mediators of
articular destruction in damaged joints55,56.
The results of this in vitro study demonstrate that clodronate has
an anabolic effect in articular cartilage and this response appears to
be transduced through the purinergic receptor pathway. After
cellular uptake by ﬂuid-phase endocytosis, clodronate is metabo-
lized into the non-hydrolyzable ATP analog AppCCl2p and released
extracellularly where it can bind to purinergic receptors resulting
in increased matrix synthesis. These ﬁndings support the previous
notion that certain bisphosphonates may be useful as adjunctive
therapies10e13 to potentially ameliorate progression of cartilage
degeneration and improve arthritis management.
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